Literature DB >> 10418544

Alzheimer disease. Report of the Council on Scientific Affairs.

R Guttman1, R D Altman, N H Nielsen.   

Abstract

Alzheimer disease (AD) takes a heavy economic, social, physical, and psychological toll on patients, families, and society. Because of the increasing life expectancy in the United States, AD is expected to afflict approximately 14 million people within the next few decades. There is currently no cure, only interventions that can temporarily ameliorate the profound cognitive losses and behavioral manifestations of the disorder. Community services are fragmented and underutilized. Physicians, in their traditional role as gatekeepers, can encourage more families to use supportive services. This article reviews the guidelines on the diagnosis and treatment of AD of the Agency for Health Care Policy and Research, the American Academy of Neurology, the Veterans Health Administration, and the American Psychiatric Association. Although these guidelines contain valuable information, they do not adequately address the role of the family physician and the need for continuity of care. Recommendations regarding AD from the Council on Scientific Affairs, which were adopted as American Medical Association policy in December 1997, are included in this article.

Entities:  

Mesh:

Year:  1999        PMID: 10418544     DOI: 10.1001/archfami.8.4.347

Source DB:  PubMed          Journal:  Arch Fam Med        ISSN: 1063-3987


  5 in total

1.  Galantamine: a pharmacoeconomic review of its use in Alzheimer's disease.

Authors:  Katherine A Lyseng-Williamson; Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

2.  Fine mapping of the chromosome 12 late-onset Alzheimer disease locus: potential genetic and phenotypic heterogeneity.

Authors:  W K Scott; J M Grubber; P M Conneally; G W Small; C M Hulette; C K Rosenberg; A M Saunders; A D Roses; J L Haines; M A Pericak-Vance
Journal:  Am J Hum Genet       Date:  2000-03       Impact factor: 11.025

3.  Linkage and association study of late-onset Alzheimer disease families linked to 9p21.3.

Authors:  S Züchner; J R Gilbert; E R Martin; C R Leon-Guerrero; P-T Xu; C Browning; P G Bronson; P Whitehead; D E Schmechel; J L Haines; M A Pericak-Vance
Journal:  Ann Hum Genet       Date:  2008-08-28       Impact factor: 1.670

4.  Long-term safety and tolerability of rivastigmine in patients with Alzheimer's disease switched from donepezil: an open-label extension study.

Authors:  Gary S Figiel; Barbara Koumaras; Xiangyi Meng; John Strigas; Ibrahim Gunay
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

5.  A network based method for analysis of lncRNA-disease associations and prediction of lncRNAs implicated in diseases.

Authors:  Xiaofei Yang; Lin Gao; Xingli Guo; Xinghua Shi; Hao Wu; Fei Song; Bingbo Wang
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.